WO2009117661A3 - Carrier neutralization assay - Google Patents

Carrier neutralization assay Download PDF

Info

Publication number
WO2009117661A3
WO2009117661A3 PCT/US2009/037811 US2009037811W WO2009117661A3 WO 2009117661 A3 WO2009117661 A3 WO 2009117661A3 US 2009037811 W US2009037811 W US 2009037811W WO 2009117661 A3 WO2009117661 A3 WO 2009117661A3
Authority
WO
WIPO (PCT)
Prior art keywords
carrier
bound
hiv
target cell
assay
Prior art date
Application number
PCT/US2009/037811
Other languages
French (fr)
Other versions
WO2009117661A2 (en
Inventor
Carl Alving
Original Assignee
United States Department Of The Army, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department Of The Army, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research filed Critical United States Department Of The Army, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research
Publication of WO2009117661A2 publication Critical patent/WO2009117661A2/en
Publication of WO2009117661A3 publication Critical patent/WO2009117661A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4

Abstract

A unique assay is disclosed for evaluating neutralization of HIV -I virus. The assay uses a carrier cell that contains a lipid bilayer with lipids that allows binding of HIV-I but that cannot be infected by virus. The carrier-bound HIV-I still retains the ability to move from the carrier to a target cell when it is co-cultured with the target cell. In the assay, the carrier-bound HIV-1 is exposed to candidate neutralizing antibodies, and non-bound antibodies are washed away. The carrier-bound HlV-l containing bound antibody is then evaluated for the ability to infect any relevant target cell (such as a CD4-positive lymphocyte), and the degree of infectivity of the target cell will reflect the relative neutralizing activity (if any) of the antibody that was used to coat the carrier-bound HIV-1.
PCT/US2009/037811 2008-03-20 2009-03-20 Carrier neutralization assay WO2009117661A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7062008P 2008-03-20 2008-03-20
US61/070,620 2008-03-20

Publications (2)

Publication Number Publication Date
WO2009117661A2 WO2009117661A2 (en) 2009-09-24
WO2009117661A3 true WO2009117661A3 (en) 2009-12-30

Family

ID=41091556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/037811 WO2009117661A2 (en) 2008-03-20 2009-03-20 Carrier neutralization assay

Country Status (1)

Country Link
WO (1) WO2009117661A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
CN115753652A (en) * 2022-11-03 2023-03-07 江苏力博医药生物技术股份有限公司 Method for quantitatively detecting RhD antigen by using erythrocyte endogenous peroxidase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
US20060194247A1 (en) * 2003-02-06 2006-08-31 Matti Sallberg Glycosylated specificity exchangers
US20070264265A1 (en) * 2006-05-15 2007-11-15 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
US20060194247A1 (en) * 2003-02-06 2006-08-31 Matti Sallberg Glycosylated specificity exchangers
US20070264265A1 (en) * 2006-05-15 2007-11-15 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALVING ET AL.: "HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral- neutralizing antibodies (Review).", MOLECULAR MEMBRANE BIOLOGY, vol. 23, no. 6, November 2006 (2006-11-01), pages 453 - 465, XP008080215 *
HORAKOVA ET AL.: "Complement Mediates the Binding of HIV to Erythrocytes.", THE JOURNAL OF IMMUNOLOGY, vol. 173, 2004, pages 4236 - 4241 *
LACHGAR ET AL.: "Binding of HIV-I to RBCs involves the Duffy Antigen Receptors for Chemokines (DARC).", BIOMED & PHARMACOTHER, vol. 52, 1998, pages 436 - 439 *
MELHOP ET AL.: "Protective immune responses against West Nile virus are primed by distinct complement activation pathways.", JEM, vol. 203, no. 5, 15 May 2006 (2006-05-15), pages 1371 - 1381 *
OLLINGER ET AL.: "CD4-Negative Cells Bind Human Immunodeficiency Virus Type 1 and Efficiently Transfer Virus to T Cells.", JOURNAL OF VIROLOGY, vol. 74, no. 18, September 2000 (2000-09-01), pages 8550 - 8557 *
TANTENO ET AL.: "Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells.", PROC. NAD. ACAD. SCI. USA, vol. 86, June 1989 (1989-06-01), pages 4287 - 4290 *

Also Published As

Publication number Publication date
WO2009117661A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
HRP20201856T1 (en) Antibodies that bind to human programmed death ligand 1 (pd-l1)
WO2013070776A8 (en) Neutralizing gp41 antibodies and their use
EP3970746A3 (en) Polypeptide variants and uses thereof
CR20120042A (en) DIRECTED IMMUNOCATE PLAYERS
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
ATE549624T1 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF FLU
ATE525455T1 (en) METHOD FOR PRESERVING VIRUS PARTICLES
WO2011100708A3 (en) Assay card for sample acquisition, treatment and reaction
JP2012105660A5 (en)
WO2007047579A3 (en) A novel therapeutic target for protozoal diseases
JP2013063072A5 (en)
WO2013165972A3 (en) Anti-hepatitis b virus antibodies and use thereof
WO2009031045A3 (en) Anti-chikungunya monoclonal antibodies and uses thereof
BR112013016495A2 (en) A monoclonal antibody which recognizes human papilloma virus (HPV) L2 protein, and a HPV neutralization antibody value measuring method which uses it
WO2009051201A1 (en) Anti-bst2 antibody
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
CY1121856T1 (en) JCV NEUTRALIZING ANTIBODIES
EA201400447A1 (en) ANTIBODIES TO CD1d
WO2009117661A3 (en) Carrier neutralization assay
WO2013142300A3 (en) Jcv neutralizing antibodies
BR112014023063A2 (en) antibodies that neutralize rsv, mpv and pvm and their uses
WO2015196192A3 (en) Methods and compositions relating to dengue virus
WO2012103337A3 (en) Assays and methods to sequence microbes directly from immune complexes
EA201370030A1 (en) BIFUNCTIONAL QUANTITATIVE IN VITRO ANALYSIS OF BINDING TARGETS FOR DETECTING NEUTRALIZING ANTIBODIES TO TARGET ANTIBODIES
WO2011146120A3 (en) Assay for identifying antigens that activate b cell receptors comprising neutralizing antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09721407

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09721407

Country of ref document: EP

Kind code of ref document: A2